CoChat

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Open access
Stagg, John, Loi, Sherene, Divisekera, Upulie, Ngiow, Shin Foong, Duret, Helene, Yagita, Hideo, Teng, Michele W., Smyth, Mark J. · 2011 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2/ErbB-2), has become the mainstay of treatment for HER2-positive breast cancer. Nevertheless, its exact mechanism of action has not been fully elucidated. Although several studies suggest that Fc receptor-expressing immune cells are involved in trastuzumab therapy, the relative contribution of lymphocyte-mediated cellular cytotoxicity and antitumor cytokines remains unknown. We report here that anti-ErbB-2 mAb therapy is dependent on the release of type I and type II IFNs but is independent of perforin or FasL. Our study thus challenges the notion that classical antibody-dependent, lymphocyte-mediated cellular cytotoxicity is important for trastuzumab. We demonstrate that anti-ErbB-2 mAb therapy of experimental tumors derived from MMTV-ErbB-2 transgenic mice triggers MyD88-dependent signaling and primes IFN-γ-producing CD8+ T cells. Adoptive cell transfer of purified T cell subsets confirmed the essential role of IFN-γ-producing CD8+ T cells. Notably, anti-ErbB-2 mAb therapy was independent of IL-1R or IL-17Ra signaling. Finally, we investigated whether immunostimulatory approaches with antibodies against programmed death-1 (PD-1) or 41BB (CD137) could be used to capitalize on the immune-mediated effects of trastuzumab. We demonstrate that anti-PD-1 or anti-CD137 mAb can significantly improve the therapeutic activity of anti-ErbB-2 mAb in immunocompetent mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1016569108

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 496

Metadata

Authors
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J.
Affiliations
  • Peter MacCallum Cancer Centre (AU)
  • Institut Jules Bordet (BE)
  • The University of Melbourne (AU)
  • Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
Corresponding author
Smyth, Mark J.
Venue
Proceedings of the National Academy of Sciences
Published
2011-04-11
Volume
108
Issue
17
Pages
7142-7147
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2066471812
Cited by
496
References
34
Citations by year
2026: 15 · 2025: 24 · 2024: 29 · 2023: 36 · 2022: 33 · 2021: 43 · 2020: 22 · 2019: 45 · 2018: 39 · 2017: 37 · 2016: 45 · 2015: 40 · 2014: 32 · 2013: 27 · 2012: 19
FWCI
13.87
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Funders
  • Medical Research Council
  • National Health and Medical Research Council
  • Japan Society for the Promotion of Science (22240089)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
trastuzumab, HER2-positive breast cancer, type I interferon, interferon-gamma, MyD88 signaling, antibody-dependent cellular cytotoxicity, Fc receptors, adoptive T cell therapy, anti-PD-1 therapy, immune checkpoint blockade, combination immunotherapy
MeSH terms
Trastuzumab, Animals, Antibodies, Monoclonal, Antigens, Surface, Antineoplastic Combined Chemotherapy Protocols, Humans, Interferon Type I, Interferon-gamma, Mice, Inbred BALB C, Mice, Transgenic, Mammary Neoplasms, Animal, Mice, SCID, CD8-Positive T-Lymphocytes, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Adoptive Transfer, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice, Tumor Necrosis Factor Receptor Superfamily, Member 9, Receptors, Interleukin-1 Type I, Receptors, Interleukin-17, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. https://app.cochat.ai/papers/10.1073/pnas.1016569108
The paper
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1016569108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.